V-Bio Ventures launches second fund at 78m
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at 78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1123 entries already.
Entries by Thomas Gabrielczyk
Abingworth raises US-$465m for new life sciences fund
/in News/by Thomas GabrielczykThe transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
/in News/by Thomas GabrielczykAs rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
/in News/by Thomas GabrielczykGerman CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise 35m in Series A extension
/in News/by Thomas GabrielczykEnthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
German antibodies in demand in USA
/in News/by Thomas GabrielczykA US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags 10.8m from EIC Accerator Fund
/in News/by Thomas GabrielczykIsraels Omnix Medical has been granted 10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany orders antibody therapies from USA
/in News/by Thomas GabrielczykGermany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign 220m deal
/in News/by Thomas GabrielczykFrench Servier SA and the UKs MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads 21m round into Neurent Medical
/in News/by Thomas GabrielczykIrish life sciences company Neurent Medical has closed a 21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.